Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 4;8(7):e85.
doi: 10.1002/hem3.85. eCollection 2024 Jul.

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes

Kazimierz Groen  1   2 , Febe Smits  1   2 , Kazem Nasserinejad  3   4 , Mark-David Levin  5 , Josien C Regelink  6 , Gert-Jan Timmers  7 , Esther G M de Waal  8 , Matthijs Westerman  9 , Gerjo A Velders  10 , Koen de Heer  11 , Rineke B L Leys  12 , Roel J W van Kampen  13 , Claudia A M Stege  1   2   4 , Maarten R Seefat  1   2 , Inger S Nijhof  1   14 , Ellen van der Spek  15 , Saskia K Klein  6   16 , Niels W C J van de Donk  1   2 , Paula F Ypma  17 , Sonja Zweegman  1   2
Affiliations

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes

Kazimierz Groen et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Kazimierz Groen: BMS and Beigene: speakers bureau (no personal funding). Febe Smits: No conflicts of interest. Kazem Nasserinejad: No conflicts of interest. Mark‐David Levin: Support for attending meetings and/or travel: Janssen, Takeda. Josien C. Regelink: No conflicts of interest. Gert‐Jan Timmers: Participation on an Advisory Board: Novartis; Travel, Accommodations, Expenses; Novartis, Janssen. Esther G. M. de Waal: No conflicts of interest. Matthijs Westerman: No conflicts of interest. Gerjo A. Velders: No conflicts of interest. Koen de Heer: No conflicts of interest. Rineke B. L. Leys: No conflicts of interest. Roel J. W. van Kampen: No conflicts of interest. Claudia A. M. Stege: Speaker's Bureau: Sanofi, Celgene/Bristol Myers Squibb, Takeda; Consulting or Advisory Role: Sanofi, Janssen. Maarten R. Seefat: No conflicts of interest. Inger S. Nijhof: Payment or honoraria for lectures, presentations, or educational events: Janssen, Celgene/Bristol Myers Squibb, Sanofi. Ellen van der Spek: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Janssen. Saskia K. Klein: No conflicts of interest. Niels W. C. J. van de Donk: Consulting or Advisory Role: Janssen, Celgene, Bristol Myers Squibb, Novartis, Amgen, Servier, Takeda, Bayer, Roche, Pfizer, Abbvie, Adaptive (no personal funding); Research Funding: Janssen, Celgene, Amgen, Novartis, Bristol Myers Squibb, Cellectis. Paula F. Ypma: Payment or honoraria for presentations: Janssen; Support for attending meetings and/or travel: Janssen. Sonja Zweegman: Consulting or Advisory Role: Janssen‐Cilag, Takeda, Celgene/Bristol Myers Squibb, Sanofi, Oncopeptides (no personal funding); Research Funding: Janssen, Takeda.

Figures

Figure 1
Figure 1
Overall survival for patients reclassified from frail (Simplified‐FI) to intermediate‐fit (IMWG‐FI) compared to patients intermediate‐fit based on both scores (A) or frail based on both scores (B).
See this image and copyright information in PMC

References

    1. Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068‐2074. 10.1182/blood-2014-12-615187 - DOI - PMC - PubMed
    1. Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant‐ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM‐020) trial. Leukemia. 2020;34(1):224‐233. 10.1038/s41375-019-0539-0 - DOI - PMC - PubMed
    1. Facon T, Cook G, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone in transplant‐ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36(4):1066‐1077. 10.1038/s41375-021-01488-8 - DOI - PMC - PubMed
    1. Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant‐ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE. Clin Lymphoma Myeloma Leuk. 2021;21(11):785‐798. 10.1016/j.clml.2021.06.005 - DOI - PubMed
    1. Larocca A, Bonello F, Gaidano G, et al. Dose/schedule‐adjusted Rd‐R vs continuous Rd for elderly, intermediate‐fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027‐3036. 10.1182/blood.2020009507 - DOI - PubMed

LinkOut - more resources